Genetic Disease Licensing Pharma Companies Sales 
XTalks
DECEMBER 29, 2022
Vertex is planning to submit a Biologics License Application (BLA) by the end of the first quarter of 2023 and the company says it is also on track to submit exa-cel to UK and European Union (EU) regulators by the end of the year. As such, most gene therapies in late-stage clinical trials are in oncology or rare disease indications.
XTalks
DECEMBER 13, 2023
Now, let’s delve into the list of the top ten fastest growing biotech companies in 2023, ranked by their compound annual growth rate (CAGR). These companies were identified through The Americas’ Fastest-Growing Companies 2023 list by the Financial Times. million, compared to $1.1 million for the same period in 2022.
Expert insights. Personalized for you.
52 
Let's personalize your content